טוען...
Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and human...
שמור ב:
| הוצא לאור ב: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7385100/ https://ncbi.nlm.nih.gov/pubmed/32719371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-17446-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|